Research Perspectives:

Targeting TOR dependence in cancer

Matthew R. Janes and David A. Fruman _

PDF  |  How to cite

Oncotarget. 2010; 1:69-76. https://doi.org/10.18632/oncotarget.110

Metrics: PDF 3595 views  |   ?  


Received: May 3, 2010, Accepted: May 5, 2010, Published: May 10, 2010

A challenge in cancer therapy has been to identify targets whose function is essential for survival of malignant cells but not normal cells. This Perspective discusses recent evidence that novel inhibitors of the kinase TOR can provide an unprecedented balance of anti-cancer efficacy and tolerability.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 110